AbbVie Inc. has announced a collaboration and license option agreement with ADARx Pharmaceuticals to develop next-generation small interfering RNA (siRNA) therapies across multiple therapeutic areas, including neuroscience, immunology, and oncology. This partnership aims to leverage AbbVie's expertise in biotherapeutic drug development and commercialization with ADARx's proprietary RNA technology. Under the terms of the agreement, ADARx will receive a $335 million upfront payment and may receive additional contingent payments, including option-related fees and milestone payments. The collaboration seeks to advance siRNA therapies as a novel therapeutic modality, focusing on regulating gene expression and protein production to treat difficult-to-treat diseases.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.